Brief: Vaxart starts early-stage study for its pill-based vaccine for norovirus
11/03/2025 12:57
March 11 (Reuters) - Vaxart Inc VXRT.O: VAXART ANNOUNCES CLINICAL TRIAL INITIATION OF NOROVIRUS ORAL PILL VACCINE CANDIDATE VAXART INC - TOPLINE DATA EXPECTED AS EARLY AS MID-2025 VAXART INC - PHASE 1 TRIAL TO EVALUATE SECOND-GENERATION VACCINE AGAINST FIRST-GENERATION VAXART INC - PHASE 2 STUDY COULD BEGIN AS EARLY AS SECOND HALF OF 2025 VAXART INC - PHASE 3 TRIAL COULD BEGIN AS EARLY AS 2026 Source text: nGNX9TFzR7 Further company coverage: VXRT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts